Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stok Raporu

Piyasa değeri: US$2.3b

Arrowhead Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Arrowhead Pharmaceuticals CEO'su Chris Anzalone, Dec2007 tarihinde atandı, in görev süresi 16.92 yıldır. in toplam yıllık tazminatı $ 9.92M olup, şirket hissesi ve opsiyonları dahil olmak üzere 9.1% maaş ve 90.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.99% ine doğrudan sahiptir ve bu hisseler $ 68.88M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.4 yıl ve 14 yıldır.

Anahtar bilgiler

Chris Anzalone

İcra Kurulu Başkanı

US$9.9m

Toplam tazminat

CEO maaş yüzdesi9.1%
CEO görev süresi16.9yrs
CEO sahipliği3.0%
Yönetim ortalama görev süresi6.4yrs
Yönetim Kurulu ortalama görev süresi14yrs

Son yönetim güncellemeleri

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Recent updates

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Oct 04
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jun 12
Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: Hoping Something Sticks

May 27

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

May 21
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

May 17

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25
Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10
Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

CEO Tazminat Analizi

Chris Anzalone'un ücretlendirmesi Arrowhead Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$539m

Mar 31 2024n/an/a

-US$471m

Dec 31 2023n/an/a

-US$297m

Sep 30 2023US$10mUS$903k

-US$205m

Jun 30 2023n/an/a

-US$181m

Mar 31 2023n/an/a

-US$150m

Dec 31 2022n/an/a

-US$155m

Sep 30 2022US$12mUS$863k

-US$176m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$183m

Sep 30 2021US$25mUS$837k

-US$141m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020n/an/a

-US$103m

Sep 30 2020US$14mUS$786k

-US$85m

Jun 30 2020n/an/a

-US$24m

Mar 31 2020n/an/a

US$10m

Dec 31 2019n/an/a

US$53m

Sep 30 2019US$2mUS$674k

US$68m

Jun 30 2019n/an/a

US$46m

Mar 31 2019n/an/a

US$10m

Dec 31 2018n/an/a

-US$29m

Sep 30 2018US$2mUS$643k

-US$54m

Tazminat ve Piyasa: Chris 'nin toplam tazminatı ($USD 9.92M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.54M ).

Tazminat ve Kazançlar: Chris 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Chris Anzalone (55 yo)

16.9yrs

Görev süresi

US$9,918,093

Tazminat

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Anzalone
CEO, President & Director16.9yrsUS$9.92m2.99%
$ 68.9m
Kenneth Myszkowski
Chief Financial Officer14.8yrsUS$3.12m0.19%
$ 4.4m
Patrick O'Brien
COO, General Counsel & Secretary9.9yrsUS$3.31m0.23%
$ 5.3m
James Hamilton
Chief of Discovery & Translational Medicineno dataUS$3.05m0.16%
$ 3.8m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono dataVeri yokVeri yok
Vincent Anzalone
Head of Investor Relations & VPno dataVeri yokVeri yok
Howard Lovy
Director of Communications19.3yrsVeri yokVeri yok
Bruce Given
Chief Medical Scientistless than a yearUS$16.34mVeri yok
Mark Seefeld
Head of Toxicology & VPno dataVeri yokVeri yok
Aaron Tan
Head of Tax2.8yrsVeri yokVeri yok
Andy Davis
SVP of Cardiovascular & Head of Metabolic Franchiseno dataVeri yokVeri yok
Nadia Meshkova
VP & Treasurer2.8yrsVeri yokVeri yok

6.4yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: ARWR 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.4 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Anzalone
CEO, President & Director16.9yrsUS$9.92m2.99%
$ 68.9m
Mark Davis
Founder and Founder & Director of Insert Therapeutics Inc & Calandono dataVeri yokVeri yok
Douglass Given
Chairman of the Board14yrsUS$474.60k0.11%
$ 2.6m
Michael Perry
Independent Lead Director12.9yrsUS$459.60k0.074%
$ 1.7m
William Waddill
Independent Director6.8yrsUS$469.60k0.026%
$ 609.6k
Ching-Lung Lai
Member of Hepatitis B Clinical Advisory Boardno dataVeri yokVeri yok
Robert Gish
Chairman of Hepatitis B Clinical Advisory Boardno dataVeri yokVeri yok
Mauro Ferrari
Independent Director14.3yrsUS$459.60k0.037%
$ 848.9k
Jeffrey Teckman
Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Boardno dataVeri yokVeri yok
Stephen Locarnini
Member of Hepatitis B Clinical Advisory Boardno dataVeri yokVeri yok
Johnson Lau
Member of Hepatitis B Clinical Advisory Boardno dataVeri yokVeri yok
Carlo Ferrari
Member of Hepatitis B Clinical Advisory Boardno dataVeri yokVeri yok

14.0yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ARWR 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 14 yıldır).